In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7.2 ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

The detailed results ... an average weight reduction of 20.2% compared to 13.7% with Wegovy at 72 weeks using the treatment-regimen estimand, 1 a 47% greater relative weight loss.

With subcutaneously-administered tirzepatide, which mimics the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) hormones, patients had a 20.2% reduction in weight ...

(MENAFN- Mid-East Info) Participants achieved an average weight loss of 20.2 ... at 72 weeks using treatment-regimen estimand, 1 a 47% greater relative weight loss. Participants using tirzepatide ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the safety and efficacy of the injectable drugs. Learn more about the results of ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction ... or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Dosing began at 2.5 mg for tirzepatide ...

Weight-loss medications ... study's findings. "The results are consistent with prior trials, confirming tirzepatide’s advantage over semaglutide’s single GLP-1 action," Londono, who is based ...